Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin vs Glimepiride in T2DM and CAD
NCT03693560Phase 4Completed
- Sponsor
- Damanhour University
- Start
- Oct 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of vildagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Damanhour University. Primary endpoints: Interleukin 1 beta at 3 months, High sensitivity C-reactive protein at 3 months and 1 more. Started Oct 2018; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03693560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693560.